Thursday, February 27, 2014

Mylan Surges on 2014 Guidance

Mylan (MYL) reported decent Q4 results and strong guidance for 2014 and beyond this morning. For details see my notes on the Mylan Q4 2014 analyst conference call.

Mylan sees a relatively flat (from year-earlier) Q1, but full year 2014 is expected between $7.8 and $8.2 million. Non-GAAP EPS is expected between $3.25 and $3.60.

The growth is based on new product ramps and expected approvals. Mylan sells generic drugs, so it has a large base of offerings and adds many new therapies each year. The FDA has a bit of a backlog, but that has been taken into account in the guidance. There is likely upside to the guidance if all the new therapies are approved and introduced in a timely fashion.

As of 11:37 A.M. Pacific Time, Mylan is trading at $56.47, up $5.05 or 9.8%.

In the long run Mylan looks even better. Management believes non-GAAP EPS can hit $6 per share in 2018. If you can wait that the long the stock should be worth roughly $120 per share.

No comments:

Post a Comment